Tissue plasminogen activator on admission is an important predictor of 30-day mortality in patients with acute myocardial infarction undergoing primary angioplasty


      Tissue plasminogen activator (tPA) is emerging as an important risk factor for coronary heart disease, but the association between tPA concentration and mortality in acute myocardial infarction (AMI) remains uncertain. We studied the relationship between tPA antigen level on admission and 30-day mortality in 226 consecutive patients with AMI undergoing primary angioplasty. Death within 30 days occurred in 13 patients (5.7%). The concentration of tPA was significantly higher among the 13 patients who died than among the 213 who survived (26.5 ± 16.3 versus 12.5 ± 8.5 ng/mL, p < 0.001). Compared with those in the lowest quartile (<9 ng/mL), patients in the highest quartile (>16 ng/mL) had a relative risk of subsequent death of 13.1 (p = 0.014). In a Cox regression model, a tPA concentration >19 ng/mL was independently associated with mortality (HR 12.1, 95% CI, 1.9–76.7, p = 0.001). This cutoff value had a 76.9% sensitivity and an 85.9% specificity for predicting 30-day mortality. tPA concentration was also higher in patients with severe heart failure (20.9 ± 14.2 ng/mL versus 11.7 ± 7.5 ng/mL, p = 0.001) or ventricular tachyarrhythmia (24.3 ± 13.9 ng/mL versus 12.2 ± 8.4 ng/mL, p = 0.001). In conclusions, elevated tPA antigen at initial presentation in patients with AMI was associated with higher short-term risk of death, suggesting that tPA may be a useful prognostic biomarker for the early risk stratification of these patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Panteghini M.
        Role and importance of biochemical markers in clinical cardiology.
        Eur Heart J. 2004; 25: 1187-1196
        • Morrow D.A.
        • Antman E.M.
        • Charlesworth A.
        • et al.
        TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an In TIME II trial substudy.
        Circulation. 2000; 102: 2031-2037
        • Eagle K.A.
        • et al.
        A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry.
        JAMA. 2004; 291: 2727-2733
        • The Multicenter Postinfarction Research Group
        Risk stratification and survival after myocardial infarction.
        N Engl J Med. 1983; 309: 331-336
        • Kooistra T.
        • Schrauwen Y.
        • Arts J.
        • Emeis J.J.
        Regulation of endothelial cell t-PA synthesis and release.
        Int J Hematol. 1994; 59: 233-255
        • Pradhan A.D.
        • LaCroix A.Z.
        • Langer R.D.
        • et al.
        Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women.
        Circulation. 2004; 110: 292-300
        • Ridker P.M.
        • Vaughan D.E.
        • Stampfer M.J.
        • et al.
        Endogenous tissue-type plasminogen activator and risk of myocardial infarction.
        Lancet. 1993; 341: 1165-1168
        • Lowe G.D.O.
        • Danesh J.
        • Lewington S.
        • et al.
        Tissue plasminogen activator antigen and coronary heart disease: prospective study and meta-analysis.
        Eur Heart J. 2004; 25: 252-259
        • Thompson S.G.
        • Kienast J.
        • Pyke S.D.M.
        • Haverkate F.
        • van de Loo J.C.W.
        Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.
        N Engl J Med. 1995; 332: 635-641
        • Held C.
        • Hjemdahl P.
        • Rehnqvist N.
        • et al.
        Fibrinolytic v and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol. Results from the Angina Prognosis study in Stockholm.
        Circulation. 1997; 95: 2380-2386
        • Ganti A.K.
        • Potti A.
        • Yegnanarayan R.
        Plasma tissue plasminogen activator and plasminogen activator-1 levels in acute myocardial infarction.
        Pathophysiol Haemost Thromb. 2002; 32: 80-84
        • Fortunato A.
        • Giavarina D.
        Decision limit for troponin I on ADVIA: Centaur and evaluation of the analytical precision at low concentrations.
        Clin Lab. 2003; 49: 251-253
        • Wu A.H.
        • Packer M.
        • Smith A.
        • et al.
        Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study.
        Clin Chem. 2004; 50: 867-873
        • Sanchez A.
        • Mirabel J.L.
        • Barrenechea E.
        • et al.
        Evaluation of an improved immunoturbidimetic assay for serum C-reactive protein on a COBAS INTEGRA 400 Analyzer.
        Clin Lab. 2002; 48: 313-317
        • Dorn-Beineke A.
        • Dempfle C.E.
        • Bertsch T.
        • Wisser H.
        Evaluation of the automated coagulation analyzer Sysmex CA-7000.
        Thromb Res. 2005; 116: 171-179
        • Oger E.
        • Leroyer C.
        • Bressollette L.
        • et al.
        Evaluation of a new, rapid, and quantitative D-dimer test in patients with suspected pulmonary embolism.
        Am J Respir Crit Care Med. 1998; 158: 65-70
        • Stroop D.M.
        • Glueck C.J.
        • Tracy T.M.
        • Schumacher H.R.
        Measurement of plasminogen activator inhibitor type 1 antigen: comparison of Tintelize and Imubind methods.
        Blood Coagul Fibrinolysis. 1994; 5: 865-872
        • Munagala V.K.
        • Burnett Jr., J.C.
        • Redfield M.M.
        The natriuretic peptides in cardiovascular medicine.
        Curr Probl Cardiol. 2004; 29: 707-769
        • de Lemos J.A.
        • Morrow D.A.
        • Bentley J.H.
        • et al.
        The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
        N Engl J Med. 2001; 345: 1014-1021
        • Antman E.M.
        • Tanasijevic M.J.
        • Thompson B.
        • et al.
        Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes.
        N Engl J Med. 1996; 335: 1342-1349
        • Wu A.H.
        • Apple F.S.
        • Gibler W.B.
        • et al.
        National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases.
        Clin Chem. 1999; 45: 1104-1121
        • de Maat M.P.
        • Trion A.
        C-reactive protein as a risk factor versus risk marker.
        Curr Opin Lipidol. 2004; 15: 651-657
        • Biasucci L.M.
        CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper.
        Circulation. 2004; 110: e560-e567
        • Zebrack J.S.
        • Anderson J.L.
        • Maycock C.A.
        • et al.
        Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction.
        Am J Cardiol. 2002; 89: 145-149
        • Nordenhem A.
        • Wiman B.
        Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA/inhibitor complexes.
        Scand J Clin Lab Invest. 1998; 58: 475-483
        • Geppert A.
        • Graf S.
        • Beckmann R.
        • et al.
        Concentration of endogenous tPA antigen in coronary artery disease: relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease.
        Arterioscler Thromb Vasc Biol. 1998; 18: 1634-1642
        • Kruithof E.K.O.
        • Mestries J.C.
        • Gascon M.P.
        • Ythier A.
        The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation: effect of interleukin 6.
        Thromb Haemost. 1997; 77: 905-910
        • Chia S.
        • Qadan M.
        • Newton R.
        • Ludlam C.A.
        • Fox K.A.
        • Newby D.E.
        • et al.
        Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans.
        Arterioscler Thromb Vasc Biol. 2003; 23: 695-701
        • de Bono D.
        Significance of raised plasma concentrations of tissue-type plasminogen activator and plasminogen activator inhibitor in patients at risk from ischaemic heart disease.
        Br Heart J. 1994; 71: 504-507